Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

2001. Effectiveness of self management training in type 2 diabetes: a systematic review of randomized controlled trials

Effectiveness of self management training in type 2 diabetes: a systematic review of randomized controlled trials Effectiveness of self management training in type 2 diabetes: a systematic review of randomized controlled trials Effectiveness of self management training in type 2 diabetes: a systematic review of randomized controlled trials Norris S L, Engelgau M M, Narayan K M Authors' objectives The objectives were: to ascertain the effectiveness of self-management training in type 2 diabetes (...) the effectiveness of diabetes education, the inclusion criteria specified that studies should be of participants aged greater than 18 years, with type 2 diabetes and any degree of disease severity and any co-morbidity. Studies of children and adolescents were excluded. Where reported, the mean age of participants in the included studies was: 33 to 65 years for studies of knowledge or information interventions (didactic); 45 to 66 years for studies of knowledge or information interventions (collaborative); 35

2001 DARE.

2002. Cost-effectiveness of using angiotensin-converting enzyme inhibitors to slow nephropathy in normotensive patients with diabetes type II and microalbuminuria

by Hoechst Marion Roussel. Bibliographic details Sakthong P, Tangphao O, Eiam-Ong S, Kamolratanakul P, Supakankunti S, Himathongkam T, Yathavong K. Cost-effectiveness of using angiotensin-converting enzyme inhibitors to slow nephropathy in normotensive patients with diabetes type II and microalbuminuria. Nephrology 2001; 6(2): 71-77 Indexing Status Subject indexing assigned by CRD MeSH Adult; Albuminuria /drug therapy /prevention & Angiotensin-Converting Enzyme Inhibitors /therapeutic use /economics (...) ; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies /drug therapy /economics /prevention & Drug Costs; Humans; Life Expectancy; Renal Dialysis; Thailand; control; control /economics AccessionNumber 22001001399 Date bibliographic record published 31/01/2003 Date abstract record published 31/01/2003 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York Homepage Options Print PubMed record Original

2001 NHS Economic Evaluation Database.

2003. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus Huang E S, Meigs J B, Singer D E Authors' objectives To quantify the cardiovascular benefit of lowering cholesterol, blood-pressure and glucose levels in patients with type 2 diabetes (...) included in the review Studies that compared intensive medication control of cardiovascular risk factor levels using drug therapy with placebo or routine risk factor reduction were eligible. Studies of the management of cholesterol, blood-pressure and blood glucose were included. Participants included in the review Studies that either focused on or included subgroups of adults (greater than 18 years old) with type 2 diabetes mellitus were eligible. Outcomes assessed in the review Studies were eligible

2001 DARE.

2004. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review

The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review Chilcott J, Wight J, Lloyd Jones M, Tappenden P Authors' objectives To evaluate the incremental clinical and cost (...) -effectiveness of pioglitazone in its licenced indication (UK product licence), in combination with insulin, and as monotherapy (unlicensed indications). The licensed indication specifies the following: 'only in oral combination treatment of type 2 diabetes mellitus in patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea'; 'in combination with metformin only in obese patients'; 'in combination with a sulphonylurea only

2001 DARE.

2005. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials

Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials Boule N G, Haddad E, Kenny G P, Wells G A, Sigal R J Authors' objectives To determine the effect of exercise (...) on glycosylated haemoglobin (HbA1c) and body mass in people with type 2 diabetes. Searching The following databases were searched up to December 2000: MEDLINE (from 1966), EMBASE (from 1980), SPORTDiscus (from 1949), HealthSTAR (from 1975), Dissertation Abstracts (from 1861) and the Cochrane Controlled Trials Register. The reference lists of major textbooks, reviews and all identified studies were handsearched. Experts were contacted for details of unpublished studies. Non-English language publications were

2001 DARE.

2006. Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes

Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes Glanz M, Garber A J, Mancia G, Levenstein M Authors' objectives To assess the safety and efficacy of alpha1-adrenergic agonists in patients with type 2 diabetes. Searching (...) ; captopril, mean dose of 57 mg/day; atenolol, 75 mg/day; and nifedipine, mean dose 54 mg/day. The duration of the studies ranged from 1 week to 21 months (mean: 18.8 weeks). Participants included in the review Hypertensive patients with type 2 diabetes mellitus were eligible. Non-diabetic and normal patients were also included in two primary studies, although it is unclear whether the results from these patients were included in the meta-analyses. The primary studies excluded patients with severe

2001 DARE.

2007. Patient diabetes education in the management of adult type 2 diabetes

Patient diabetes education in the management of adult type 2 diabetes Patient diabetes education in the management of adult type 2 diabetes Patient diabetes education in the management of adult type 2 diabetes Corabian P, Harstall C Authors' objectives The authors' apparent objective was to determine what evidence was available in the published literature about the efficacy and effectiveness of the use of existing patient diabetes education (PDE) programmes, in terms of the long-term patient (...) outcomes, in the management of type 2 diabetes in adults,. Searching MEDLINE, CINAHL, HealthSTAR, EMBASE, ERIC, PsycINFO, the Cochrane Library, the ISTAHC database, and Dissertation Abstracts were searched for papers published between 1966 and May 2000. The following keywords were used: 'diabetes mellitus', 'diabetes', 'diabetes mellitus, non-insulin-dependent', 'effectiveness', 'impact', 'evaluation', 'outcome assessment (health care)', 'outcome and process assessment (health care)', 'program

2001 DARE.

2008. A model educational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA)

A model educational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA) A model educational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA) A model educational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA) Gagliardino J J, Etchegoyen G Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was an educational programme for people with type 2 diabetes. The programme was based on four weekly teaching units (90-120 minutes each, providing general concepts about diabetes, self-monitoring, foot examinations, and booklets

2001 NHS Economic Evaluation Database.

2009. [Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes: pharmacoeconomic analysis of cost-effectiveness]

of NPH insulin before sleeping (L2). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised Type 1 diabetes patients aged at least 18 years, who had been on insulin therapy for at least one year (basal values of insulin C-peptide of less than 0.3 nM), and had been diagnosed as diabetic for at least 2 years. Patients under other treatments were excluded. Setting The setting was primary care. The economic study (...) analyses were not conducted, the external validity of the analysis was fairly low. The study enrolled a sample of patients with Type 2 diabetes and this was reflected in the conclusions of the analysis. Implications of the study Lispro insulin proved to be a cost-effective intervention in patients suffering from Type 1 diabetes. The authors suggested that further studies should rely on long-term effectiveness data and a large sample of patients. Source of funding Financed in part by Bayer Diagnostics

2001 NHS Economic Evaluation Database.

2010. A computer simulation model for cost-effectiveness analysis of mass screening for type 2 diabetes mellitus

summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two 10-year mass screening programmes for Type 2 diabetes mellitus (DM) were examined. The programmes were biennial and 5-yearly screening. Type of intervention Screening. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population referred to a hypothetical cohort of individuals (...) , $8,881 for 50 - 59 years, $16,700 for 60 - 69 years, and $36,467 for over 70 years Authors' conclusions Mass screening for Type 2 diabetes mellitus (DM) with a 5-year inter-screening interval represented a cost-effective option in Taiwan, especially among young persons. CRD COMMENTARY - Selection of comparators The authors compared the two screening programmes with the no-screening option to evaluate the extra costs and benefits of the interventions under study. However, no explication was given

2001 NHS Economic Evaluation Database.

2011. The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy

for the treatment of hypertension in type II diabetic patients in the UK and Italy. International Journal of Clinical Practice 2001; 55(2): 84-92 PubMedID Other publications of related interest 1. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. 2. Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. American Heart Journal 1990;121:293-8. Indexing Status (...) Subject indexing assigned by NLM MeSH Antihypertensive Agents /economics /therapeutic use; Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /complications /economics; Diabetic Angiopathies /drug therapy /economics; Doxazosin /economics /therapeutic use; Drug Therapy, Combination; Female; Great Britain; Humans; Hypertension /drug therapy /economics; Italy; Lipids /blood; Male; Middle Aged; Risk Assessment AccessionNumber 22001000858 Date bibliographic record published 31/03/2002 Date abstract record

2001 NHS Economic Evaluation Database.

2012. Clinical impact and health economic consequences of post-transplant type 2 diabetes mellitus

Clinical impact and health economic consequences of post-transplant type 2 diabetes mellitus Clinical impact and health economic consequences of post-transplant type 2 diabetes mellitus Clinical impact and health economic consequences of post-transplant type 2 diabetes mellitus Chilcott J B, Whitby S M, Moore R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) benefits. Further research should focus on patients who receive renal transplantation at 35 years, for whom conservative estimates were used in the effectiveness analysis. Source of funding None stated. Bibliographic details Chilcott J B, Whitby S M, Moore R. Clinical impact and health economic consequences of post-transplant type 2 diabetes mellitus. Transplantation Proceedings 2001; 33(5A Supplement): 32S-39S PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult

2001 NHS Economic Evaluation Database.

2013. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No 51)

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No 51) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2001 NHS Economic Evaluation Database.

2014. Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands

Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Hutubessy R C, Vondeling H, de Sonnaville J J, Colly L P, Smit J L, Heine R J Record Status This is a critical abstract (...) for the management of patients with Type 2 diabetes initiating insulin therapy. The service consisted of a patient registration and recall system plus a laboratory. A dietician and a specific diabetes educator provided diabetes education. A supervising diabetologist could be consulted by telephone 24 hours a day. The patients were monitored at least at 3-month intervals and feedback was provided to the GP. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study

2001 NHS Economic Evaluation Database.

2015. An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54)

An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54) An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54) An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54) Gray A, Clarke P, Raikou M, Adler A, Stevens R, Neil A, Cull C, Stratton I, Holman R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health interventions under study were two antihypertensive therapies, atenolol (a beta-blocker, daily dose of 50 mg, increasing to 100 mg if required) and captopril (an angiotensin converting enzyme inhibitor (ACE), 25 mg twice daily increasing to 50 mg twice daily), in patients with type-2 diabetes. Type

2001 NHS Economic Evaluation Database.

2016. Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting

Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting Gozzoli V, Palmer A J, Brandt A, Spinas G A Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of various interventions for the management of Type 2 diabetes (non insulin dependent; hereafter, referred to as diabetes). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

2001 NHS Economic Evaluation Database.

2017. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors: a meta-analysis of individual patient data

treatment regimes were included: captopril, 12.5 to 50 mg, twice daily; lisinopril, 10 to 20 mg/day; enalapril, 10 to 20 mg/day; perindopril, 2 mg/day; and ramipril, 1.25 or 5 mg/day. The treatment duration, where reported, ranged from 0 to 52 years. Participants included in the review Non-hypertensive patients with type 1 diabetes mellitus, as defined by the individuals trials, were eligible for inclusion. Patients could only have microalbuminuria, which was defined as an albumin excretion rate of 20 (...) with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors: a meta-analysis of individual patient data. Annals of Internal Medicine 2001; 134(5): 370-379 PubMedID Original Paper URL Other publications of related interest 1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. 2. Goldstein H. Multilevel statistical models. London: Edward Arnold; 1995. 3. Whitehead A, Whitehead J. A general parametric approach to the meta

2001 DARE.

2018. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. (Abstract)

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. Most antidiabetic agents target only 1 of several underlying causes of diabetes. The complementary actions of the antidiabetic agents metformin hydrochloride and rosiglitazone maleate may maintain optimal glycemic control in patients with type 2 diabetes; therefore, their combined use may be indicated for patients whose diabetes is poorly controlled by metformin (...) alone.To evaluate the efficacy of metformin-rosiglitazone therapy in patients whose type 2 diabetes is inadequately controlled with metformin alone.Randomized, double-blind, placebo-controlled trial from April 1997 and March 1998.Thirty-six outpatient centers in the United States.Three hundred forty-eight patients aged 40 to 80 years with a mean fasting plasma glucose level of 12.0 mmol/L (216 mg/dL), a mean glycosylated hemoglobin level of 8.8%, and a mean body mass index of 30.1 kg/m2 were

2000 JAMA Controlled trial quality: predicted high

2019. Guidance on rosiglitazone for Type 2 diabetes mellitus

Guidance on rosiglitazone for Type 2 diabetes mellitus Guidance on rosiglitazone for Type 2 diabetes mellitus Guidance on rosiglitazone for Type 2 diabetes mellitus National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on rosiglitazone for Type 2 diabetes mellitus. London (...) : National Institute for Clinical Excellence (NICE) 2000 Authors' objectives To provide guidance on the use of rosiglitazone for Type 2 diabetes mellitus. Authors' conclusions Guidance 1.1 Rosiglitazone is effective at reducing blood glucose when added to oral monotherapy (metformin or sulphonylurea) for patients who have inadequate control of blood glucose on these conventional agents alone. 1.2 Patients with inadequate blood glucose control on oral monotherapy (metformin or sulphonylurea) should first

2000 Health Technology Assessment (HTA) Database.

2020. Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients

Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Pons JM Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pons JM (...) . Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). IN01/2000. 2000 Authors' objectives To review the available evidence on continuous subcutaneous infusion of insulin with portable pump in diabetes type I patients. Authors' conclusions Continuous subcutaneous external infusion insulin pumps were found to be effective to achieve good metabolic control, the closest

2000 Health Technology Assessment (HTA) Database.